邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

华法林在新型口服抗凝药物时代的地位

万征,  李永乐

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(2): 108-111
万征, 李永乐. 华法林在新型口服抗凝药物时代的地位[J]. 协和医学杂志, 2018, 9(2): 108-111. doi: 10.3969/j.issn.1674-9081.2018.02.003
引用本文: 万征, 李永乐. 华法林在新型口服抗凝药物时代的地位[J]. 协和医学杂志, 2018, 9(2): 108-111. doi: 10.3969/j.issn.1674-9081.2018.02.003
shu
Zheng Wan, Yongle Li. The Status of Warfarin in the Era of Novel Oral Anticoagulants[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 108-111. doi: 10.3969/j.issn.1674-9081.2018.02.003
Citation: Zheng Wan, Yongle Li. The Status of Warfarin in the Era of Novel Oral Anticoagulants[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 108-111. doi: 10.3969/j.issn.1674-9081.2018.02.003
shu

华法林在新型口服抗凝药物时代的地位

doi: 10.3969/j.issn.1674-9081.2018.02.003

  • 天津医科大学总医院心内科，天津 300052

详细信息
    通讯作者:

    万征  电话：022-60362426, E-mail:wanzhhh@vip.126.com

  • 中图分类号: R453.9; R543

The Status of Warfarin in the Era of Novel Oral Anticoagulants

  • Department of Cardiology, Tianjin Medical University General Hospital, Tianjin 300052, China

More Information

    摘要
  • 摘要: 抗凝治疗是血栓栓塞性疾病，尤其是肺栓塞防治的重要措施。华法林作为经典的抗凝药物，从20世纪50年代起用于治疗血栓栓塞性疾病。相比华法林，新型口服抗凝药物(novel oral anticoagulants，NOACs)具有药代动力学稳定、可固定剂量使用、无须频繁监测凝血功能、与药物及食物相互作用少、药物安全性良好等突出优点。NOACs给临床医生带来更多用药选择的同时，也挑战了华法林在抗凝领域的地位。然而目前很多临床情况下，华法林的抗凝价值仍不可替代。
    Abstract: Anticoagulation therapy is an important measure for the treatment and prevention of thromboembolic diseases, especially pulmonary embolism. Warfarin, as a classic anticoagulant drug, has been applied to thromboembolic diseases since the 1950s. Compared with warfarin, novel oral anticoagulants(NOACs) have the advantages of stable pharmacokinetics, fixed-dose usage, no need for frequent monitoring of coagulation function, less interaction with drugs and foods, and good drug safety. The emergence of NOACs has given clinicians more choice of drugs, and it also challenges warfarin's position in the field of anticoagulation. However, there is no medicine to replace warfarin yet in many clinical scenarios. Warfarin still has the value of its existence.
    • HTML全文
    • 参考文献(18)
  • [1] van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis[J]. JAMA, 2002, 288:2441-2448. doi:  10.1001/jama.288.19.2441
    [2] ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J]. Lancet, 2006, 367:1903-1912. doi:  10.1016/S0140-6736(06)68845-4
    [3] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy toprevent stroke in patients who have nonvalvular atrial fibrillation [J]. Ann Intern Med, 2007, 146:857-867. doi:  10.7326/0003-4819-146-12-200706190-00007
    [4] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2009, 361:1139-1151. doi:  10.1056/NEJMoa0905561
    [5] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J]. N Engl J Med, 2011, 365:883-891. doi:  10.1056/NEJMoa1009638
    [6] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2011, 365:981-992. doi:  10.1056/NEJMoa1107039
    [7] Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2013, 369: 2093-2104. doi:  10.1056/NEJMoa1310907
    [8] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials [J]. Lancet, 2014, 383:955-962. doi:  10.1016/S0140-6736(13)62343-0
    [9] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Europace, 2016, 18:1609-1678. doi:  10.1093/europace/euw295
    [10] Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis [J].Circulation, 2014, 129: 764-772. doi:  10.1161/CIRCULATIONAHA.113.004450
    [11] Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism [J]. N Engl J Med, 2013, 369:1406-1415. doi:  10.1056/NEJMoa1306638
    [12] Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism [J]. N Engl J Med, 2013, 369: 799-808. doi:  10.1056/NEJMoa1302507
    [13] Investigators EP, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism [J]. N Engl J Med, 2012, 366:1287-1297. doi:  10.1056/NEJMoa1113572
    [14] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report [J]. Chest, 2016, 149:315-352. doi:  10.1016/j.chest.2015.11.026
    [15] Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabiga-tran versus warfarin in patients with mechanical heart valves [J].N Engl J Med, 2013, 369:1206-1214. doi:  10.1056/NEJMoa1300615
    [16] Hoffman R, Brenner B. The promise of novel direct oral anticoagulants[J]. Best Pract Res Clin Haematol, 2012, 25:351-360. doi:  10.1016/j.beha.2012.06.004
    [17] 中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会.华法林抗凝治疗的中国专家共识[J].中华内科杂志, 2013:76-82. doi:  10.3760/cma.j.issn.0578-1426.2013.01.027
    [18] Gallagher AM, Setakis E, Plumb JM, et al. Risks of strokeand mortality associated with suboptimal anticoagulation in atrial fibrillation patients [J]. Thromb Haemost, 2011, 106: 968-977. doi:  10.1160/TH11-05-0353
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  287
  • HTML全文浏览量:  37
  • PDF下载量:  401
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-29
  • 刊出日期:  2018-03-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！